Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts

• DOI: 10.1182/bloodadvances.2017012005
• Publication Date: 2018-02-08T09:53:12Z
• Authors: Javid Gaziev; Antonella Isgrò; Pietro Sodani; Katia Paciaroni; Gioia De Angelis; Marco Marziali; Michela Ribersani; Cecilia Alfieri; Alessandro Lanti; Tiziana Galluccio; Gaspare Adorno; Marco Andreani
• Keywords: Graft Rejection; Male; Adolescent; Receptors, Antigen, T-Cell, alpha-beta; Antigens, CD19; 610; Specialties of internal medicine; Graft vs Host Disease; Antigens, CD34; Haploidentical; Lymphocyte Depletion; Settore MED/05 - PATOLOGIA CLINICA; 03 medical and health sciences; 0302 clinical medicine; Receptors; Humans; Antigens; Preschool; Child; Retrospective Studies; alpha-beta; Transplantation; CD19; Graft Survival; Hematopoietic Stem Cell Transplantation; T-Cell; Survival Analysis; 3. Good health; Hemoglobinopathies; Treatment Outcome; RC581-951; Antigen; Child, Preschool; Transplantation, Haploidentical; CD34

Key Points TCRαβ+/CD19+-depleted haplo-HCT is associated with a reduced incidence of graft failure in patients with hemoglobinopathies. The major challenges of haplo-HCT in hemoglobinopathies are delayed immune reconstitution and associated morbidity and mortality.